When:
Monday, May 21, 2018
4:00 PM - 5:00 PM CT
Where: Ward Building, 5-230, 303 E. Chicago Avenue, Chicago, IL 60611 map it
Audience: Faculty/Staff - Student - Post Docs/Docs - Graduate Students
Contact:
Liz Barrera Murphy
(312) 503-4892
Group: Department of Pharmacology Seminars
Category: Lectures & Meetings
The Department of Pharmacology welcomes David S. Bredt, M.D., Ph.D., Global Head Neuroscience Discovery and Site Head, La Jolla Janssen Pharmaceutical Companies of Johnson & Johnson
Below is a description of the seminar as told by Dr. Bredt:
Targeted therapy for neuropsychiatric disorders requires selective modulation of dysfunctional neuronal pathways. Receptors relevant to CNS disorders typically have associated proteins discretely expressed in specific neuronal pathways; these accessory proteins provide a new dimension for drug discovery. Recent studies show that targeting a TARP auxiliary subunit of AMPA receptors selectively modulates neuronal excitability in specific forebrain pathways relevant to epilepsy. Other medicinally important ion channels, gated by glutamate, g-aminobutyric acid (GABA), and acetylcholine, also have associated proteins, which may be druggable. This emerging pharmacology of receptor-associated proteins provides a new approach for improving drug efficacy while mitigating side effects.